Anebulo Pharmaceuticals, Inc. (ANEB)

Over the past six months, Anebulo Pharmaceuticals' stock (ANEB) has experienced significant movements and has been impacted by several key events. On November 13, 2025, Anebulo Pharmaceuticals reported its First Quarter Fiscal Year 2026 financial results, announcing a net loss of $2.2 million, or $(0.05) per share, which exceeded analysts' expectations. On September 29, 2025, the company released its Fourth Quarter and Fiscal Year 2025 financial results, reporting a net loss of $2.1 million for the quarter. On September 25, 2025, Anebulo announced that the first subjects were dosed in a Phase 1 single ascending dose (SAD) study of an intravenous (IV) formulation of selonabant, which is being developed for acute cannabis-induced toxicity in children. On September 12, 2025, Anebulo Pharmaceuticals provided an update on a proposed "going private transaction" and strategic alternatives, with the Board reviewing all options, including the proposed going private transaction and a related reverse stock split, a sale of assets, or a merger. In the past six months, ANEB stock has seen a substantial increase of 127.18%, but more recently, the price decreased by -15.22% in the past month and fell by -6.02% on November 26, 2025. The stock's 52-week high was $3.42 and its 52-week low was $0.80.

Given that Anebulo Pharmaceuticals is a clinical-stage biotechnology company developing a treatment for acute medical conditions (cannabis toxicity), there is no indication of demand seasonality for its products or services in the traditional market sense. The demand for its lead product, selonabant, once approved, would likely be driven by the incidence of acute cannabinoid intoxication and related conditions, rather than seasonal fluctuations.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for cannabis toxicity, operating within the Healthcare sector, specifically in the Biotechnology industry. The company is dedicated to providing pharmaceutical services and developing novel solutions for individuals experiencing cannabinoid overdose and substance addiction. Its lead product candidate is selonabant (ANEB-001), a small molecule antagonist of the cannabinoid binding receptor type-1 (CB1), being developed to rapidly reverse the negative effects of cannabis-induced toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication (ACI). The company is also prioritizing the development of an intravenous (IV) formulation of selonabant, particularly as a potential treatment for pediatric patients with acute cannabis-induced CNS depression, believing this pathway may offer a faster timeline to approval.

Anebulo Pharmaceuticals, Inc. operates exclusively in the United States and is headquartered in Lakeway, Texas.

As a clinical-stage biotechnology company with its lead product candidate still in clinical trials, Anebulo Pharmaceuticals' brand reputation is primarily tied to its scientific progress, clinical trial results, and regulatory interactions rather than consumer perception. Its reputation would be influenced by the successful advancement of selonabant through clinical phases and positive engagement with regulatory bodies like the FDA.

Anebulo Pharmaceuticals (NASDAQ: ANEB) is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 54.08% of the company, while insiders own 78.18%. Major institutional owners include 22nw LP, Nantahala Capital Management LLC, The Vanguard Group, Inc., BlackRock, Inc., LVW Advisors LLC, King Luther Capital Management Corp, Goldman Sachs Group Inc., MANGROVE PARTNERS IM, LLC, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, Ikarian Capital, LLC, MILLENNIUM MANAGEMENT LLC, and CITADEL ADVISORS LLC. Key individual owners include Aron R. English, who is the largest individual shareholder, owning 20.12 million shares, representing 48.98% of the company, and Joseph F. Lawler, who was noted as the largest shareholder in 2021, holding 51% of shares outstanding.